CYP1A2 and metabolic dysfunction-associated steatotic liver disease: Decrease in hepatic CYP1A2 content has been reported previously in other liver pathologies, i.e. non-alcoholic fatty liver disease (NAFLD), and at mRNA level—in alcoholic liver disease (ALD), primary sclerosing cholangitis (PSC) and hepatitis C virus (HCV)-induced liver damage.